Objective. The aim of the present study was to investigate the effect of gout on left ventricular (LV) diastolic function and left atrial volume (LAV).
Introduction
Hyperuricaemia is a metabolic condition that has become quite common over the past few decades. Gout is the main clinical issue associated with hyperuricaemia and is divided into three stages, including asymptomatic hyperuricaemia, gouty arthritis without tophi and gouty tophi, according to the severity of gout. Several epidemiological studies have reported a positive association between uric acid (UA) and cardiovascular disease [1] .
Elevated serum UA levels are an independent predictor of cardiovascular events and all-cause mortality in patients with coronary artery disease [2] . Hyperuricaemia has a significant association with poor outcomes in heart failure patients [3] . There is also an association between increased serum UA levels and permanent atrial fibrillation [4, 5] . Kim et al. [6] reported that hyperuricaemia may increase the risk of coronary heart disease (CHD) events, independent of traditional CHD risk factors. Furthermore, Cicoira et al. [7] assessed the effects of hyperuricaemia on left ventricular (LV) remodelling and found that elevated serum UA levels impaired LV diastolic function. Mitsuhashi et al. [8] also reported that serum UA concentration independently and positively associated with LV hypertrophy. These findings suggest that hyperuricaemia accelerates the occurrence and deterioration of cardiovascular disease owing to LV remodelling mediated by chronic oxidative stress under hyperuricaemia. Whether hyperuricaemia contributes to excessive cardiovascular risk in gout patients remains unknown. Clinically, we believe that the severity of gout, rather than hyperuricaemia per se, is more representative of chronic inflammation status in gout patients. Thus the impact of the existence of gout on LV diastolic dysfunction needs to be explored. Left atrial volume (LAV) may reflect the severity of LV diastolic dysfunction. Therefore LAV has been termed glycosylated haemoglobin of diastolic dysfunction. The aims of the present study were to investigate the effects of the existence of gout on LV diastolic function and consequently LAV in gout patients.
Methods

Subjects and study design
In this prospective study, patients with hyperuricaemia or gouty arthritis who underwent echocardiography examinations were enrolled in this study between October 2010 and February 2013. Age-matched individuals without hyperuricaemia or gout who also underwent echocardiography examinations because of palpitation or dyspnoea on exercise were included in this study and served as controls. Initially a total of 200 patients were enrolled in this study. Exclusion criteria included the presence of moderate or severe valvular disease, dilated or hypertrophic cardiomyopathy, LV systolic dysfunction [defined as a LV ejection fraction (EF) <55%] [9] , left bundle branch block, second-or three-degree atrioventricular conduction block, permanent cardiac pacemaker implantation, atrial arrhythmias (such as atrial fibrillation, atrial flutter or atrial tachycardia documented by electrocardiography), congenital heart disease or a history of previous cardiac surgery. Patients were also excluded if they had poor echocardiographic images for analysis. A total of 27 patients were not enrolled because of the presence of LV systolic dysfunction (n = 2), hypertrophic cardiomyopathy (n = 2), permanent cardiac pacemaker implantation (n = 2), atrial fibrillation (n = 2) and poor echocardiographic images for analysis (n = 19). Thus the final study population consisted of 173 patients.
This study was approved by the Chang Gung Medical Foundation Institutional Review Board (IRB 100-3022B) and informed consent was obtained from all patients. The clinical data recorded from the enrolled patients included age, sex, height, body weight, systolic blood pressure, serum creatinine levels, serum UA levels and the absence or presence of hypertension, diabetes mellitus, hypercholesterolaemia and medications for gouty arthritis. Asymptomatic hyperuricaemia was defined as UA 57 mg/dl without clinically painful joint histories. The diagnosis of gouty arthritis was made according to the ACR/Wallace criteria [10] . Patients who had been diagnosed with gouty arthritis using ACR criteria and received medication were also included in the gouty arthritis group. Gouty arthritis patients who had multiple nodules in the periarticular and subcutaneous tissue, particularly in the toes, fingers, elbows, knees, Achilles tendons and rims of the ears or had one nodule proved to contain urate crystals by polarized light microscopy were classified in the gouty tophi group. Hypertension was defined as systolic blood pressure 5140 mmHg and/or diastolic blood pressure 590 mmHg. Additionally, patients who were receiving antihypertensive medication were also considered hypertensive. Diabetes mellitus was defined as a fasting plasma glucose level 5126 mg/dl. Patients receiving oral anti-glucose drugs or insulin for diabetes mellitus control were also considered to have diabetes mellitus. Hypercholesterolaemia was defined as either the usage of cholesterol-lowering medication or having a total serum cholesterol 5190 mg/dl in the absence of cholesterol-lowering medication [11] .
Echocardiography
All subjects received transthoracic echocardiographic examinations at rest in the left lateral decubitus position using a Philips iE33 US system (Philips Healthcare, the Netherlands) with an S5-1 transducer. The left atrial (LA) diameter in the end-systolic phase, thickness of the interventricular septum (IVS) and posterior wall (PW) in the end-diastolic phase and the LV end-diastolic and end-systolic dimensions were all determined using the M-mode in the parasternal long-axis view according to the recommendations of the American Society of Echocardiography [12] . The left ventricular ejection fraction (LVEF) was calculated using the Simpson method and the LV mass was estimated by the Devereux formula. Then the LV mass index was obtained as LV mass/body surface area (BSA). Mitral inflow velocities were evaluated with a 1-to 2-mm sample volume placed at the mitral valve tip by pulse-wave Doppler in the apical four chamber view. Diastolic peak early (E) and late (A) transmitral flow velocity and the E-to-A ratio (E/A) were measured. In the apical four-chamber view, the peak systolic mitral annular velocity (s 0 ), peak early diastolic mitral annular velocity (e 0 ) and peak late diastolic annular velocity (a 0 ) were obtained by pulse-wave tissue Doppler imaging (TDI) at the septal site of the mitral annulus. The E/e 0 ratio was used as an index of LV filling pressure [13] . LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV) and biplane LVEF were measured in the apical four-chamber and apical two-chamber views using the biplane modified Simpson's method. Then the LVEDV and left ventricular end-systolic diameter (LVESD) indexes were calculated as LVEDV/BSA and LVESV/BSA. An M-mode recording of the long axis was taken from the lateral side of the tricuspid annulus in an apical four-chamber view. The maximal distance of endocardial motion during the systolic phase was defined as the tricuspid annular plane systolic excursion (TAPSE). The TAPSE can represent right ventricular systolic function [14] . All of the echocardiographic parameters were measured from an average of three beats.
Assessment of LAV
LAV was also measured in the apical four-chamber and apical two-chamber views using the biplane modified Simpson's method [1517] . Maximal, pre-contraction and minimal LAVs were measured just before mitral valve opening, at the beginning of the P wave and at mitral valve closure, respectively. The following indexes of LA function were calculated: maximal LAV index (LAVi) was calculated as maximal LAV/BSA, pre-contraction LAVi was calculated as pre-contraction LAV/BSA and minimal LAVi was calculated as minimal LAV/BSA. Then the total LA stroke volume (LASV) was calculated as maximal LAV À minimal LAV, the passive LASV was calculated as maximal LAV À pre-contraction LAV and the active LASV was calculated as pre-contraction LAV À minimal LAV. Similarly, during a cardiac cycle, the total left atrial ejection fraction (LAEF) was defined as (maximal LAV À minimal LAV)/maximal LAV Â 100%, passive LAEF was defined as (maximal LAV À pre-contraction LAV)/ maximal LAV Â 100% and active LAEF was defined as (pre-contraction LAV À minimal LAV)/pre-contraction LAV Â 100%.
Statistical analysis
Statistical analysis was performed using SPSS 18.0 statistical software (SPSS, Chicago, IL, USA). Continuous data are presented as mean (S.D.) and dichotomous data as number (%). Comparisons of continuous variables between groups were performed using analysis of variance. Categorical variables were compared using the 2 test.
Univariate correlations were determined by using Pearson's coefficient for continuous variables and the point-biserial coefficient for dichotomous variables. Multiple regression analyses were performed to determine the associations between gout stage with maximal LAVi, pre-contraction LAVi and the minimal LAVi. The first multivariate model adjusted for age, UA, creatinine, BSA, LV mass index and LVEDV index. The second multivariate model adjusted for mitral E/A, e 0 , e 0 /a 0 , and E/e 0 . Statistical significance was set at P < 0.05. In 20 randomly selected subjects, the interobserver and intraobserver variabilities in E/e 0 and maximal LAVi measurements were assessed by the coefficient of variation, where differences between measurements were expressed as the ratio of the standard deviation to the mean. Interobserver variability was assessed by two independent observers and intraobserver variability by one observer twice within a 2-week period. The interobserver variability of E/e 0 was 3.3% and maximal LAV was 2.2%. The intraobserver variability of E/e 0 was 1.8% and maximal LAV was 1.5%.
Results
General characteristics
The final study population consisted of 173 patients. Patients were divided into four gout stages: stage 0, age-matched control (n = 35); stage 1, asymptomatic hyperuricaemia (n = 30); stage 2, gouty arthritis without tophi (n = 58); and stage 3, gouty tophi (n = 50). Table 1 lists the clinical characteristics of the study population. There were no significant differences between the four groups with respect to age, gender and history of diabetes mellitus, hypertension, hypercholesterolaemia and cigarette smoking. There was no significantly different urate-lowering therapy between the gouty arthritis without tophi group and gouty tophi group. But the tophi gout patients received more steroid therapy to control inflammation. However, the asymptomatic hyperuricaemia, gouty arthritis without tophi and gouty tophi groups had significantly higher serum UA levels than the control group (P < 0.001). There were no significant differences in serum UA levels between patients in the asymptomatic hyperuricaemia, gouty arthritis without tophi and gouty tophi groups [8. Left and right ventricular echocardiographic parameters
The echocardiographic parameters are summarized in Table 2 . Subjects in the gouty tophi group had a significantly thicker IVS [10.9 mm (S.D. LAV and function Table 3 lists the echocardiographic parameters in terms of LA volume and function. Maximal LAVi, pre-contraction LAVi and minimal LAVi were progressively enlarged from the control group to the gouty tophi group. Additionally, the LAVi, including maximal, pre-contraction and minimal LAVi, of the gouty tophi group was significantly larger than the control group [29. significantly different among the four groups. Table 4 lists the associations of LAVi with clinical characteristics and LV size and function in patients diagnosed with gouty arthritis with and without tophi (n = 108). All three types of LAVi were significantly and positively associated with tophi, age, IVS, LV mass index, LVEDV index, LVSV index and E/e 0 (Fig. 1) , and were significantly and negatively associated with BMI and e 0 /a 0 ratio. Furthermore, pre-contraction LAVi was significantly and negatively associated with the mitral E/A ratio. There was no association between serum UA levels and the three types of LAVi in patients with gouty arthritis. By multiple regression analysis, the association between LAVi, including maximal, precontraction and minimal LAVi, and the gout stage was significant when controlled for age, UA, creatinine, BSA, LV mass index, LVEDV index, E/A, e 0 , e 0 /a 0 , and E/e 0 (Table 5) . By binary logistic analysis, maximal LAVi was an independent predictor for the development of tophi in patients diagnosed with gouty arthritis, with an odds ratio (OR) of 1.068 per 1 ml/m 2 increment in maximal LAVi (95% CI 1.02, 1.118, P = 0.005).
Discussion
The major findings of this study are (i) the LAVi increases with the severity of gout, which is associated with LV diastolic function, and (ii) each 1 ml/m 2 increment in maximal LAVi corresponds to a 6.8% risk for the development of tophi in gouty arthritis patients.
Gout, not hyperuricaemia, positively linked to cardiovascular disease and inflammatory status
Patients with gout often present with hyperuricaemia and intense inflammatory episodes. The chronic inflammation process includes not only xanthine oxidasemediated oxidative stress, but also monosodium urate crystalmediated inflammation [18] . It has been reported that UA is strongly associated with circulating markers of inflammation in patients with congestive heart failure, and serum UA levels parallel the severity of congestive heart failure [19] . Additionally, a positive association between gout and cardiovascular events has been observed [20] . Interestingly, a recent study showed that gout, not hyperuricaemia, was linked to a higher risk of CVD [21] . To determine the role of gout in the development of CVD, this prospective study was the first to evaluate cardiac function in the different stages of gout. The different stages correspond to different durations and severity of chronic inflammation. In this study the serum UA levels of the asymptomatic hyperuricaemia, gouty arthritis without tophi and gouty tophi groups were significantly higher than those of the control group (P < 0.001); however, the serum UA levels were not significantly different between the asymptomatic hyperuricaemia, gouty arthritis without tophi and gouty tophi groups. Thus serum UA levels do not reflect the severity of gout and inflammation. The creatinine levels progressively increased from the control group to the gouty tophi group and the creatinine levels of the gouty tophi group were significantly higher than those of the control, asymptomatic hyperuricaemia and gouty arthritis without tophi groups (Table 1 ). These findings suggest that patients with gouty tophi endured a longer period of inflammation and had impaired renal function. Thus the duration of inflammation and the inflammation reaction mediated by monosodium urate crystals may play an important role in the deterioration of renal function.
LV diastolic dysfunction in patients with gout LV diastolic dysfunction occurs due to heart remodelling induced by pathophysiological stress. As the heart undergoes remodelling, the LV filling pressure increases. In previous studies using the TDI technique, E/e 0 has been shown to be an excellent predictor of LV filling pressure and a parameter of LV diastolic function [22, 23] . Elevated serum UA levels are associated with diastolic dysfunction in congestive heart failure (CHF) patients with LVEF<45% due to oxygen free radicalsmediated endothelial damage resulting from increased xanthine oxidase activity [7] . In the present study, however, hyperuricaemia was not significantly associated with E/e 0 (r = 0.054, P = 0.484). Interestingly, E/e 0 progressively increased from the control group to the gouty tophi group (Table 2 ) and E/e 0 was significantly associated with gout stage (r = 0.253, P = 0.001). There are two possible explanations for these observations: (i) Patients with gout may have received medical treatment to decrease UA and xanthine oxidase activity, and in turn, oxidative free radicalmediated injury. Therefore serum UA levels alone cannot reflect the severity and duration of 
FIG. 1
Relationship of the ratio of transmitral and myocardial peak early diastolic velocities (E/e 0 ) and left atrial volume index (LAVi) in patients with gouty arthritis (n = 108) inflammation in gout patients. (ii) Gout patients present with not only increased xanthine oxidase levels, but also monosodium urate crystalmediated inflammatory cytokines, including TNF-a and IL-1b [18] , which have been implicated in the pathogenesis of myocardial dysfunction [24] . Thus classifying patients by gout stage appears to be a good indicator of the severity and duration of the chronic inflammation in gout patients. Patients diagnosed with gouty tophi that suffered from chronic severe inflammation also had relatively worse LV diastolic function. In general, LV diastolic dysfunction is frequently associated with LV hypertrophy. We also found that the LV mass index in the gouty tophi group was significantly higher than that of the control, asymptomatic hyperuricaemia and gouty arthritis without tophi groups (Table 2) .
LA volume and function in patients with gout
There are three phases of LA function within the cardiac cycle: phase 1, which acts as a 'reservoir' that receives blood from the pulmonary venous circulation during ventricular systole and isovolumetric relaxation to achieve maximal LAV; phase 2, which acts as a 'conduit' for passive transfer of blood into the LV during the early phase of ventricular diastole and after mitral valve opening, and represents passive LAEF; and phase 3, which acts as a 'contractile' chamber that actively empties blood into the LV immediately before the onset of LV systole, and represents active LAEF. Accordingly, there are three types of LAV: maximal, pre-contraction and minimal LAV, which are measured just before mitral valve opening, at the beginning of the P wave and at mitral valve closure in a cardiac cycle, respectively. LA enlargement is mostly the result of pressure and/or volume overload and can serve as an index of atrial remodelling [25] . In this study we demonstrated that maximal LAVi, pre-contraction LAVi and minimal LAVi progressively increased from the control group to gouty tophi group (Table 3) and gout stage was an independent predictor of LA enlargement (Table 5) . However, there were no significant differences between the four groups in LA function in terms of total LAEF, passive LAEF and active LAEF (Table 3 ). These findings suggest that volume remodelling of the LA occurs before functional remodelling of the LA in gout patients. Interestingly, UA was not associated with LAVi, including maximal, pre-contraction and minimal LAVi. This indicates that the severity of gout, not serum UA levels per se, affects LA volume remodelling. Thus several factors may play an important role in LA remodelling in gout patients, including oxidative stress mediated by active xanthine oxidase, the duration of inflammation and inflammation mediated by monosodium urate crystals. In this study, maximal LAVi was found to be an independent predictor for the development of tophi in patients diagnosed with gouty arthritis, with an OR of 1.068 for every increment in maximal LAVi (95% CI 1.02, 1.118, P = 0.005). Every increment in maximal LAVi corresponded to a 6.8% risk for the development of tophi in gouty arthritis patients.
Positive association between LAV remodelling and LV diastolic dysfunction in patients with gouty arthritis
In the present study, LAVi, including maximal LAVi, pre-contraction LAVi and minimal LAVi, was positively associated with E/e 0 in gouty arthritis patients (Fig. 1) . The relationship between E/e 0 and maximal LAVi in patients diagnosed with gouty arthritis can be expressed by the following linear regression equation: maximal LAVi = 1.036 E/e 0 + 16.382 (r = 0.327, P < 0.001). This suggests that gout impairs LV compliance, which increases LV filling pressure. During ventricular diastole, the LA is directly exposed to LV pressure through the open mitral valve. Consequently LA pressure increases in order to maintain adequate LV filling, which results in increased LA wall tension and LA enlargement. Therefore LAV may reflect the severity of diastolic dysfunction in gouty arthritis patients.
Study limitations
There are several limitations in the present study that need to be addressed. First, this is a cross-sectional study. We recognize that follow-up cohort studies are necessary to demonstrate that an enlargement of the LA is a predictor of cardiac events in patients diagnosed with gouty arthritis. Additionally, further non-invasive assessments of LA deformation using speckle-tracking echocardiography may be used to support the notion that LAV is a predictor of cardiac events in gouty arthritis patients. Second, we found that the severity of gout had an impact on LV diastolic dysfunction and LAV remodelling. Although the biological link between gout and heart remodelling is not yet fully understood, we hypothesize that patients with gout develop LV diastolic dysfunction and undergo LAV remodelling through not only oxidative stress mediated by active xanthine oxidase under hyperuricaemia, but also complex inflammation triggered by monosodium urate crystals. However, the biological mechanisms responsible for cardiac remodelling in gout patients required additional studies.
Conclusions
The severity of gout is significantly associated with worse LV diastolic dysfunction and LA enlargement in gout patients. Additionally, a high maximal LAVi predicted the development of tophi and may serve as a predictor of adverse cardiovascular events related to LA and LV remodelling in this setting.
Rheumatology key messages
. Left atrial volume (LAV) increases with the severity of gout. . Increased LAV predicts the development of tophi in gout patients.
